Fig. 12.

Personalised LNP-mRNA induces systematic DC maturation, and reverses the immunosuppression in TME, therefore enhances ICI cancer immunotherapy efficacy. (a) Schematic representation of anti-tumor mechanism of cationic lipid-tumor derived mRNA vaccine combined with anti-PD-L1 mAbs. (b) Representative TEM images of LNP-mRNA internalized by DC2.4 cells (scale bars: 500 nm). (c) In vivo distribution of LNP-mRNA encoding Cre (cAMP response element) in different organs. (d) The experimental timeline and B16F10-OVA tumor growth curves of mice received different nanoformulations as indicated. (e)The percentages of PD-1+CD8⁺ splenocytes derived from B16F10-OVA bearing mice Reprinted with permission from Ref. [160]. Copyright 2018, American Chemical Society.